Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03473756
Brief Title: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)

First Submitted : March 16, 2018
First Submitted that Met QC Criteria : March 21, 2018
First Posted : March 22, 2018

Last Update Submitted that Met QC Criteria : November 12, 2021
Last Update Posted : November 15, 2021